Oncotarget: Geriatric nutritional risk index - prognostic marker of esophageal carcinoma

October 16, 2020

OncotargetVolume 11, Issue 29 reported that In multivariate analyses, serum albumin, GNRI, pathological tumor-node-metastasis stage, and tumor differentiation were independent prognostic factors for CSS.

In pTNM stage I, multivariate analysis identified C-reactive protein and GNRI as independent prognostic factors for CSS.

In univariate analyses in pTNM stages II and III, only low GNRI and low serum albumin levels, respectively, were significantly associated with worse CSS.

In patients with low GNRI, CSS was significantly worse than in those with normal GNRI, especially in pTNM stages I and II groups, but not in stage III group.

Preoperative GNRI may sort patients into low- or high-risk groups for shorter CSS, especially in those with pTNM stage I and II ESCC.

Dr. Noriyuki Hirahara from The Shimane University Faculty of Medicine said, "Patients with advanced esophageal cancer presenting with dysphagia often experience malnutrition as well as impairment of performance status and quality of life."

Serum albumin is a clinically relevant indicator of nutritional status, such as malnutrition and cachexia.

Recently, it has been widely accepted that the GNRI was strongly associated with mortality in elderly hospitalized patients and in patients with various cancers.

However, to the best of the authors knowledge, there have been few reports on the prognostic significance of the GNRI in patients with esophageal squamous cell carcinoma.

In this study, they have investigated whether the GNRI is a useful predictor of long-term survivals in patients with ESCC who underwent a curative esophagectomy.

"In this study, they have investigated whether the GNRI is a useful predictor of long-term survivals in patients with ESCC who underwent a curative esophagectomy"


The Hirahara Research Team concluded in their OncotargetResearch Paper that, "preoperative GNRI can be used to sort patients into groups at high- or low-risk for shorter CSS after undergoing curative resection for ESCC, especially those with pTNM stage I and II ESCC; the interpretation should be done with care due to the differences in clinical background. Therefore, multicenter prospective validation of our findings is considered necessary to confirm the usefulness of GNRI as clinical therapeutic stratification marker for patients requiring more aggressive multimodality treatment or stringing surveillance.

Sign up for free Altmetric alerts about this article

DOI - https://doi.org/10.18632/oncotarget.27670

Full text - https://www.oncotarget.com/article/27670/text/

Correspondence to - Noriyuki Hirahara - norinorihirahara@yahoo.co.jp

Keywords - geriatric nutritional risk index, esophageal squamous cell carcinoma, curative esophagectomy, cancer-specific survival, pathological tumor-node-metastasis

About Oncotarget

Oncotarget is a weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology.

To learn more about Oncotarget, please visit https://www.oncotarget.com or connect with:

SoundCloud -https://soundcloud.com/oncotarget
Facebook -https://www.facebook.com/Oncotarget/
Twitter -https://twitter.com/oncotarget
LinkedIn -https://www.linkedin.com/company/oncotarget
Pinterest -https://www.pinterest.com/oncotarget/
Reddit -https://www.reddit.com/user/Oncotarget/

Oncotarget is published by Impact Journals, LLC please visit http://www.ImpactJournals.com or connect with @ImpactJrnls

Impact Journals LLC

Related Escc Articles from Brightsurf:

Oncotarget: Geriatric nutritional risk index - prognostic marker of esophageal carcinoma
Oncotarget Volume 11, Issue 29 reported that In multivariate analyses, serum albumin, GNRI, pathological tumor-node-metastasis stage, and tumor differentiation were independent prognostic factors for CSS.

Immunotherapy is beneficial in gastric and oesophageal cancers, studies show
New data presented at ESMO 2020 have shown that immunotherapy is beneficial for patients with gastric and oesophageal cancers who currently have poor survival.

Potential new therapy takes aim at a lethal esophageal cancer's glutamine addiction
Medical University of South Carolina investigators have exploited a metabolic quirk of certain cancers known as glutamine addiction to identify a potential new therapy for esophageal cancer.

Oral microbiota indicates link between periodontal disease and esophageal cancer
An analysis of bacteria present in the mouth showed that some types of bacteria that lead to periodontal disease were associated with higher risk of esophageal cancer.

Action is needed to make stagnant CO2 emissions fall
2016 marked the third year in a row when global carbon dioxide emissions remained relatively flat, but actual declines won't materialize without advances in carbon capture and storage technology and sustained growth in renewables.

Researchers find association between oral bacteria and esophageal cancer
University of Louisville School of Dentistry researchers have found a bacterial species responsible for gum disease, Porphyromonas gingivalis, is present in 61 percent of patients with esophageal squamous cell carcinoma.

Blood test for VEGF-A, TGF-B1 could help determine treatment options for esophageal cancer patients
A blood test may be beneficial in indicating neoadjuvant treatment regimens for patients with esophageal squamous cell carcinoma, according to research presented today at the American Society for Radiation Oncology's 56th Annual Meeting.

Autophagic activation with Nimotuzumab enhances chemo-radiosensitivity
Nimotuzumab, a humanized IgG1 isotype monoclonal antibody targeting epidermal growth factor receptor (EGFR), enhanced the sensitivity of esophageal squamous cell carcinoma cells with high expression of EGFR to chemo-radiotherapy, due to autophagic activation mediated by this agent.

Chinese scientists report new findings on mutations identification of esophageal cancer
The all-round work was published online today in the international journal Nature, providing a new eye-opening insight into developing novel biomarkers for therapeutic strategies of this most common form of esophageal cancer.

New discovery of biomarker to improve diagnosis, prognosis and treatment of ESCC
Scientists from the National University of Singapore have discovered a biomarker, called adenosine deaminase acting on RNA-1 , which has the potential to improve the diagnosis, prognosis and treatment of Esophageal Squamous Cell Carcinoma.

Read More: Escc News and Escc Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.